Form 4: MEI Pharma Director Nicholas Glover Receives 20,000 Stock Options

MEI Pharma, Inc. Director Nicholas Glover was granted 20,000 stock options with an exercise price of $3.07, exercisable immediately and expiring in 2035.

Summary

• Nicholas Glover, a Director of MEI Pharma, Inc. (MEIP), acquired 20,000 stock options.
• The stock options have an exercise price of $3.07 per share.
• The transaction date for the grant was July 15, 2025.
• The options are immediately exercisable as of July 15, 2025, and will expire on July 15, 2035.
• Each option represents the right to buy one share of MEI Pharma common stock.
• This grant is described as a customary annual grant to non-employee directors.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with shareholder value. It does not indicate significant positive or negative operational news for the company.

Positives

• The grant of stock options aligns the director's interests with shareholder value, as the options become more valuable if the stock price increases above the exercise price.
• The options are immediately exercisable, providing flexibility to the director.

Negatives

• The value of the options is contingent on the future stock price exceeding the exercise price of $3.07.

Risks

• The value of the stock options is entirely dependent on the future performance of MEI Pharma's common stock. If the stock price does not rise above the exercise price of $3.07, the options may expire worthless.

Future Outlook

The document does not provide explicit forward-looking statements or guidance beyond the expiration date of the options.

Management Comments

• Customary annual grant to non-employee directors of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025.

Industry Context

This filing reports a routine insider transaction related to director compensation and does not provide sufficient information to analyze broader industry trends or competitive landscape.

Comparison to Industry Standards

• This document is an insider transaction report (Form 4) detailing a specific compensation event for a director. It does not contain financial results or operational data that would allow for a detailed comparison to industry standards, comparable companies, or projects.

Related Party Transactions

• The grant of 20,000 stock options to Nicholas Glover, a Director, constitutes a related-party transaction as part of his compensation.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution if exercised, but also serves to align the director's financial incentives with the company's stock performance.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

MEI Pharma, MEIP, Stock Option, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Nicholas Glover